Magnetic resonance spectroscopy assessment of brain injury after moderate hypothermia in neonatal encephalopathy: a prospective multicentre cohort study
In neonatal encephalopathy, the clinical manifestations of injury can only be reliably assessed several years after an intervention, complicating early prognostication and rendering trials of promising neuroprotectants slow and expensive. We aimed to determine the accuracy of thalamic proton magneti...
Uloženo v:
| Vydáno v: | Lancet neurology Ročník 18; číslo 1; s. 35 - 45 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
Elsevier Ltd
01.01.2019
Elsevier Limited Lancet Pub. Group |
| Témata: | |
| ISSN: | 1474-4422, 1474-4465, 1474-4465 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | In neonatal encephalopathy, the clinical manifestations of injury can only be reliably assessed several years after an intervention, complicating early prognostication and rendering trials of promising neuroprotectants slow and expensive. We aimed to determine the accuracy of thalamic proton magnetic resonance (MR) spectroscopy (MRS) biomarkers as early predictors of the neurodevelopmental abnormalities observed years after neonatal encephalopathy.
We did a prospective multicentre cohort study across eight neonatal intensive care units in the UK and USA, recruiting term and near-term neonates who received therapeutic hypothermia for neonatal encephalopathy. We excluded infants with life-threatening congenital malformations, syndromic disorders, neurometabolic diseases, or any alternative diagnoses for encephalopathy that were apparent within 6 h of birth. We obtained T1-weighted, T2-weighted, and diffusion-weighted MRI and thalamic proton MRS 4–14 days after birth. Clinical neurodevelopmental tests were done 18–24 months later. The primary outcome was the association between MR biomarkers and an adverse neurodevelopmental outcome, defined as death or moderate or severe disability, measured using a multivariable prognostic model. We used receiver operating characteristic (ROC) curves to examine the prognostic accuracy of the individual biomarkers. This trial is registered with ClinicalTrials.gov, number NCT01309711.
Between Jan 29, 2013, and June 25, 2016, we recruited 223 infants who all underwent MRI and MRS at a median age of 7 days (IQR 5–10), with 190 (85%) followed up for neurological examination at a median age of 23 months (20–25). Of those followed up, 31 (16%) had moderate or severe disability, including one death. Multiple logistic regression analysis could not be done because thalamic N-acetylaspartate (NAA) concentration alone accurately predicted an adverse neurodevelopmental outcome (area under the curve [AUC] of 0·99 [95% CI 0·94–1·00]; sensitivity 100% [74–100]; specificity 97% [90–100]; n=82); the models would not converge when any additional variable was examined. The AUC (95% CI) of clinical examination at 6 h (n=190) and at discharge (n=167) were 0·72 (0·65–0·78) and 0·60 (0·53–0·68), respectively, and the AUC of abnormal amplitude integrated EEG at 6 h (n=169) was 0·73 (0·65–0·79). On conventional MRI (n=190), cortical injury had an AUC of 0·67 (0·60–0·73), basal ganglia or thalamic injury had an AUC of 0·81 (0·75–0·87), and abnormal signal in the posterior limb of internal capsule (PLIC) had an AUC of 0·82 (0·76–0·87). Fractional anisotropy of PLIC (n=65) had an AUC of 0·82 (0·76–0·87). MRS metabolite peak-area ratios (n=160) of NAA–creatine (<1·29) had an AUC of 0·79 (0·72–0·85), of NAA–choline had an AUC of 0·74 (0·66–0·80), and of lactate–NAA (>0·22) had an AUC of 0·94 (0·89–0·97).
Thalamic proton MRS measures acquired soon after birth in neonatal encephalopathy had the highest accuracy to predict neurdevelopment 2 years later. These methods could be applied to increase the power of neuroprotection trials while reducing their duration.
National Institute for Health Research UK. |
|---|---|
| AbstractList | In neonatal encephalopathy, the clinical manifestations of injury can only be reliably assessed several years after an intervention, complicating early prognostication and rendering trials of promising neuroprotectants slow and expensive. We aimed to determine the accuracy of thalamic proton magnetic resonance (MR) spectroscopy (MRS) biomarkers as early predictors of the neurodevelopmental abnormalities observed years after neonatal encephalopathy.
We did a prospective multicentre cohort study across eight neonatal intensive care units in the UK and USA, recruiting term and near-term neonates who received therapeutic hypothermia for neonatal encephalopathy. We excluded infants with life-threatening congenital malformations, syndromic disorders, neurometabolic diseases, or any alternative diagnoses for encephalopathy that were apparent within 6 h of birth. We obtained T
-weighted, T
-weighted, and diffusion-weighted MRI and thalamic proton MRS 4-14 days after birth. Clinical neurodevelopmental tests were done 18-24 months later. The primary outcome was the association between MR biomarkers and an adverse neurodevelopmental outcome, defined as death or moderate or severe disability, measured using a multivariable prognostic model. We used receiver operating characteristic (ROC) curves to examine the prognostic accuracy of the individual biomarkers. This trial is registered with ClinicalTrials.gov, number NCT01309711.
Between Jan 29, 2013, and June 25, 2016, we recruited 223 infants who all underwent MRI and MRS at a median age of 7 days (IQR 5-10), with 190 (85%) followed up for neurological examination at a median age of 23 months (20-25). Of those followed up, 31 (16%) had moderate or severe disability, including one death. Multiple logistic regression analysis could not be done because thalamic N-acetylaspartate (NAA) concentration alone accurately predicted an adverse neurodevelopmental outcome (area under the curve [AUC] of 0·99 [95% CI 0·94-1·00]; sensitivity 100% [74-100]; specificity 97% [90-100]; n=82); the models would not converge when any additional variable was examined. The AUC (95% CI) of clinical examination at 6 h (n=190) and at discharge (n=167) were 0·72 (0·65-0·78) and 0·60 (0·53-0·68), respectively, and the AUC of abnormal amplitude integrated EEG at 6 h (n=169) was 0·73 (0·65-0·79). On conventional MRI (n=190), cortical injury had an AUC of 0·67 (0·60-0·73), basal ganglia or thalamic injury had an AUC of 0·81 (0·75-0·87), and abnormal signal in the posterior limb of internal capsule (PLIC) had an AUC of 0·82 (0·76-0·87). Fractional anisotropy of PLIC (n=65) had an AUC of 0·82 (0·76-0·87). MRS metabolite peak-area ratios (n=160) of NAA-creatine (<1·29) had an AUC of 0·79 (0·72-0·85), of NAA-choline had an AUC of 0·74 (0·66-0·80), and of lactate-NAA (>0·22) had an AUC of 0·94 (0·89-0·97).
Thalamic proton MRS measures acquired soon after birth in neonatal encephalopathy had the highest accuracy to predict neurdevelopment 2 years later. These methods could be applied to increase the power of neuroprotection trials while reducing their duration.
National Institute for Health Research UK. In neonatal encephalopathy, the clinical manifestations of injury can only be reliably assessed several years after an intervention, complicating early prognostication and rendering trials of promising neuroprotectants slow and expensive. We aimed to determine the accuracy of thalamic proton magnetic resonance (MR) spectroscopy (MRS) biomarkers as early predictors of the neurodevelopmental abnormalities observed years after neonatal encephalopathy. We did a prospective multicentre cohort study across eight neonatal intensive care units in the UK and USA, recruiting term and near-term neonates who received therapeutic hypothermia for neonatal encephalopathy. We excluded infants with life-threatening congenital malformations, syndromic disorders, neurometabolic diseases, or any alternative diagnoses for encephalopathy that were apparent within 6 h of birth. We obtained T1-weighted, T2-weighted, and diffusion-weighted MRI and thalamic proton MRS 4–14 days after birth. Clinical neurodevelopmental tests were done 18–24 months later. The primary outcome was the association between MR biomarkers and an adverse neurodevelopmental outcome, defined as death or moderate or severe disability, measured using a multivariable prognostic model. We used receiver operating characteristic (ROC) curves to examine the prognostic accuracy of the individual biomarkers. This trial is registered with ClinicalTrials.gov, number NCT01309711. Between Jan 29, 2013, and June 25, 2016, we recruited 223 infants who all underwent MRI and MRS at a median age of 7 days (IQR 5–10), with 190 (85%) followed up for neurological examination at a median age of 23 months (20–25). Of those followed up, 31 (16%) had moderate or severe disability, including one death. Multiple logistic regression analysis could not be done because thalamic N-acetylaspartate (NAA) concentration alone accurately predicted an adverse neurodevelopmental outcome (area under the curve [AUC] of 0·99 [95% CI 0·94–1·00]; sensitivity 100% [74–100]; specificity 97% [90–100]; n=82); the models would not converge when any additional variable was examined. The AUC (95% CI) of clinical examination at 6 h (n=190) and at discharge (n=167) were 0·72 (0·65–0·78) and 0·60 (0·53–0·68), respectively, and the AUC of abnormal amplitude integrated EEG at 6 h (n=169) was 0·73 (0·65–0·79). On conventional MRI (n=190), cortical injury had an AUC of 0·67 (0·60–0·73), basal ganglia or thalamic injury had an AUC of 0·81 (0·75–0·87), and abnormal signal in the posterior limb of internal capsule (PLIC) had an AUC of 0·82 (0·76–0·87). Fractional anisotropy of PLIC (n=65) had an AUC of 0·82 (0·76–0·87). MRS metabolite peak-area ratios (n=160) of NAA–creatine (<1·29) had an AUC of 0·79 (0·72–0·85), of NAA–choline had an AUC of 0·74 (0·66–0·80), and of lactate–NAA (>0·22) had an AUC of 0·94 (0·89–0·97). Thalamic proton MRS measures acquired soon after birth in neonatal encephalopathy had the highest accuracy to predict neurdevelopment 2 years later. These methods could be applied to increase the power of neuroprotection trials while reducing their duration. National Institute for Health Research UK. Summary Background In neonatal encephalopathy, the clinical manifestations of injury can only be reliably assessed several years after an intervention, complicating early prognostication and rendering trials of promising neuroprotectants slow and expensive. We aimed to determine the accuracy of thalamic proton magnetic resonance (MR) spectroscopy (MRS) biomarkers as early predictors of the neurodevelopmental abnormalities observed years after neonatal encephalopathy. Methods We did a prospective multicentre cohort study across eight neonatal intensive care units in the UK and USA, recruiting term and near-term neonates who received therapeutic hypothermia for neonatal encephalopathy. We excluded infants with life-threatening congenital malformations, syndromic disorders, neurometabolic diseases, or any alternative diagnoses for encephalopathy that were apparent within 6 h of birth. We obtained T1-weighted, T2-weighted, and diffusion-weighted MRI and thalamic proton MRS 4–14 days after birth. Clinical neurodevelopmental tests were done 18–24 months later. The primary outcome was the association between MR biomarkers and an adverse neurodevelopmental outcome, defined as death or moderate or severe disability, measured using a multivariable prognostic model. We used receiver operating characteristic (ROC) curves to examine the prognostic accuracy of the individual biomarkers. This trial is registered with ClinicalTrials.gov, number NCT01309711. Findings Between Jan 29, 2013, and June 25, 2016, we recruited 223 infants who all underwent MRI and MRS at a median age of 7 days (IQR 5–10), with 190 (85%) followed up for neurological examination at a median age of 23 months (20–25). Of those followed up, 31 (16%) had moderate or severe disability, including one death. Multiple logistic regression analysis could not be done because thalamic N-acetylaspartate (NAA) concentration alone accurately predicted an adverse neurodevelopmental outcome (area under the curve [AUC] of 0·99 [95% CI 0·94–1·00]; sensitivity 100% [74–100]; specificity 97% [90–100]; n=82); the models would not converge when any additional variable was examined. The AUC (95% CI) of clinical examination at 6 h (n=190) and at discharge (n=167) were 0·72 (0·65–0·78) and 0·60 (0·53–0·68), respectively, and the AUC of abnormal amplitude integrated EEG at 6 h (n=169) was 0·73 (0·65–0·79). On conventional MRI (n=190), cortical injury had an AUC of 0·67 (0·60–0·73), basal ganglia or thalamic injury had an AUC of 0·81 (0·75–0·87), and abnormal signal in the posterior limb of internal capsule (PLIC) had an AUC of 0·82 (0·76–0·87). Fractional anisotropy of PLIC (n=65) had an AUC of 0·82 (0·76–0·87). MRS metabolite peak-area ratios (n=160) of NAA–creatine (<1·29) had an AUC of 0·79 (0·72–0·85), of NAA–choline had an AUC of 0·74 (0·66–0·80), and of lactate–NAA (>0·22) had an AUC of 0·94 (0·89–0·97). Interpretation Thalamic proton MRS measures acquired soon after birth in neonatal encephalopathy had the highest accuracy to predict neurdevelopment 2 years later. These methods could be applied to increase the power of neuroprotection trials while reducing their duration. Funding National Institute for Health Research UK. In neonatal encephalopathy, the clinical manifestations of injury can only be reliably assessed several years after an intervention, complicating early prognostication and rendering trials of promising neuroprotectants slow and expensive. We aimed to determine the accuracy of thalamic proton magnetic resonance (MR) spectroscopy (MRS) biomarkers as early predictors of the neurodevelopmental abnormalities observed years after neonatal encephalopathy.BACKGROUNDIn neonatal encephalopathy, the clinical manifestations of injury can only be reliably assessed several years after an intervention, complicating early prognostication and rendering trials of promising neuroprotectants slow and expensive. We aimed to determine the accuracy of thalamic proton magnetic resonance (MR) spectroscopy (MRS) biomarkers as early predictors of the neurodevelopmental abnormalities observed years after neonatal encephalopathy.We did a prospective multicentre cohort study across eight neonatal intensive care units in the UK and USA, recruiting term and near-term neonates who received therapeutic hypothermia for neonatal encephalopathy. We excluded infants with life-threatening congenital malformations, syndromic disorders, neurometabolic diseases, or any alternative diagnoses for encephalopathy that were apparent within 6 h of birth. We obtained T1-weighted, T2-weighted, and diffusion-weighted MRI and thalamic proton MRS 4-14 days after birth. Clinical neurodevelopmental tests were done 18-24 months later. The primary outcome was the association between MR biomarkers and an adverse neurodevelopmental outcome, defined as death or moderate or severe disability, measured using a multivariable prognostic model. We used receiver operating characteristic (ROC) curves to examine the prognostic accuracy of the individual biomarkers. This trial is registered with ClinicalTrials.gov, number NCT01309711.METHODSWe did a prospective multicentre cohort study across eight neonatal intensive care units in the UK and USA, recruiting term and near-term neonates who received therapeutic hypothermia for neonatal encephalopathy. We excluded infants with life-threatening congenital malformations, syndromic disorders, neurometabolic diseases, or any alternative diagnoses for encephalopathy that were apparent within 6 h of birth. We obtained T1-weighted, T2-weighted, and diffusion-weighted MRI and thalamic proton MRS 4-14 days after birth. Clinical neurodevelopmental tests were done 18-24 months later. The primary outcome was the association between MR biomarkers and an adverse neurodevelopmental outcome, defined as death or moderate or severe disability, measured using a multivariable prognostic model. We used receiver operating characteristic (ROC) curves to examine the prognostic accuracy of the individual biomarkers. This trial is registered with ClinicalTrials.gov, number NCT01309711.Between Jan 29, 2013, and June 25, 2016, we recruited 223 infants who all underwent MRI and MRS at a median age of 7 days (IQR 5-10), with 190 (85%) followed up for neurological examination at a median age of 23 months (20-25). Of those followed up, 31 (16%) had moderate or severe disability, including one death. Multiple logistic regression analysis could not be done because thalamic N-acetylaspartate (NAA) concentration alone accurately predicted an adverse neurodevelopmental outcome (area under the curve [AUC] of 0·99 [95% CI 0·94-1·00]; sensitivity 100% [74-100]; specificity 97% [90-100]; n=82); the models would not converge when any additional variable was examined. The AUC (95% CI) of clinical examination at 6 h (n=190) and at discharge (n=167) were 0·72 (0·65-0·78) and 0·60 (0·53-0·68), respectively, and the AUC of abnormal amplitude integrated EEG at 6 h (n=169) was 0·73 (0·65-0·79). On conventional MRI (n=190), cortical injury had an AUC of 0·67 (0·60-0·73), basal ganglia or thalamic injury had an AUC of 0·81 (0·75-0·87), and abnormal signal in the posterior limb of internal capsule (PLIC) had an AUC of 0·82 (0·76-0·87). Fractional anisotropy of PLIC (n=65) had an AUC of 0·82 (0·76-0·87). MRS metabolite peak-area ratios (n=160) of NAA-creatine (<1·29) had an AUC of 0·79 (0·72-0·85), of NAA-choline had an AUC of 0·74 (0·66-0·80), and of lactate-NAA (>0·22) had an AUC of 0·94 (0·89-0·97).FINDINGSBetween Jan 29, 2013, and June 25, 2016, we recruited 223 infants who all underwent MRI and MRS at a median age of 7 days (IQR 5-10), with 190 (85%) followed up for neurological examination at a median age of 23 months (20-25). Of those followed up, 31 (16%) had moderate or severe disability, including one death. Multiple logistic regression analysis could not be done because thalamic N-acetylaspartate (NAA) concentration alone accurately predicted an adverse neurodevelopmental outcome (area under the curve [AUC] of 0·99 [95% CI 0·94-1·00]; sensitivity 100% [74-100]; specificity 97% [90-100]; n=82); the models would not converge when any additional variable was examined. The AUC (95% CI) of clinical examination at 6 h (n=190) and at discharge (n=167) were 0·72 (0·65-0·78) and 0·60 (0·53-0·68), respectively, and the AUC of abnormal amplitude integrated EEG at 6 h (n=169) was 0·73 (0·65-0·79). On conventional MRI (n=190), cortical injury had an AUC of 0·67 (0·60-0·73), basal ganglia or thalamic injury had an AUC of 0·81 (0·75-0·87), and abnormal signal in the posterior limb of internal capsule (PLIC) had an AUC of 0·82 (0·76-0·87). Fractional anisotropy of PLIC (n=65) had an AUC of 0·82 (0·76-0·87). MRS metabolite peak-area ratios (n=160) of NAA-creatine (<1·29) had an AUC of 0·79 (0·72-0·85), of NAA-choline had an AUC of 0·74 (0·66-0·80), and of lactate-NAA (>0·22) had an AUC of 0·94 (0·89-0·97).Thalamic proton MRS measures acquired soon after birth in neonatal encephalopathy had the highest accuracy to predict neurdevelopment 2 years later. These methods could be applied to increase the power of neuroprotection trials while reducing their duration.INTERPRETATIONThalamic proton MRS measures acquired soon after birth in neonatal encephalopathy had the highest accuracy to predict neurdevelopment 2 years later. These methods could be applied to increase the power of neuroprotection trials while reducing their duration.National Institute for Health Research UK.FUNDINGNational Institute for Health Research UK. |
| Author | Mitchell, Martin Abernethy, Laurence J Bassett, Paul Clarke, Paul Mendoza, Josephine Pattnayak, Santosh Satodia, Prakash Harigopal, Sundeep Harigopal, Sundeeep Muthukumar, Priya Swamy, Ravi Huertas, Angela Sashikumar, Palaniappan Yajamanyam, Kiran Harizaj, Helen Kalra, Vaneet Kariholu, Ujwal Bainbridge, Alan Thayyil, Sudhin Ganesh, Vijayakumar Dixon, Jennifer Atreja, Gaurav Chawla, Sanjay Sharp, David J Shankaran, Seetha Oliveira, Vânia Wayte, Sarah Soe, Aung Price, David Montaldo, Paolo Lally, Peter J English, Philip |
| AuthorAffiliation | e Neonatal Unit, Royal Victoria Infirmary, Newcastle, UK a Centre for Perinatal Neuroscience, Imperial College London, London, UK f Neonatal Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK k Neonatal-Perinatal Medicine, Wayne State University, Detroit, MI, USA b Oliver Fisher Neonatal Unit, Medway NHS Foundation Trust, Kent, UK d Neonatal Unit, Imperial College Healthcare NHS Trust, London, UK g Neonatal Unit, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK j Computational, Cognitive and Clinical Neuroimaging Laboratory, Imperial College London, London, UK h Neonatal Unit, Liverpool Women's NHS Foundation Trust, Liverpool, UK i Neonatal Unit, University College London Hospitals NHS Foundation Trust, London, UK c Statsconsultancy, Amersham, UK |
| AuthorAffiliation_xml | – name: j Computational, Cognitive and Clinical Neuroimaging Laboratory, Imperial College London, London, UK – name: a Centre for Perinatal Neuroscience, Imperial College London, London, UK – name: g Neonatal Unit, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK – name: b Oliver Fisher Neonatal Unit, Medway NHS Foundation Trust, Kent, UK – name: h Neonatal Unit, Liverpool Women's NHS Foundation Trust, Liverpool, UK – name: c Statsconsultancy, Amersham, UK – name: d Neonatal Unit, Imperial College Healthcare NHS Trust, London, UK – name: i Neonatal Unit, University College London Hospitals NHS Foundation Trust, London, UK – name: k Neonatal-Perinatal Medicine, Wayne State University, Detroit, MI, USA – name: f Neonatal Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK – name: e Neonatal Unit, Royal Victoria Infirmary, Newcastle, UK |
| Author_xml | – sequence: 1 givenname: Peter J surname: Lally fullname: Lally, Peter J organization: Centre for Perinatal Neuroscience, Imperial College London, London, UK – sequence: 2 givenname: Paolo surname: Montaldo fullname: Montaldo, Paolo organization: Centre for Perinatal Neuroscience, Imperial College London, London, UK – sequence: 3 givenname: Vânia surname: Oliveira fullname: Oliveira, Vânia organization: Centre for Perinatal Neuroscience, Imperial College London, London, UK – sequence: 4 givenname: Aung surname: Soe fullname: Soe, Aung organization: Oliver Fisher Neonatal Unit, Medway NHS Foundation Trust, Kent, UK – sequence: 5 givenname: Ravi surname: Swamy fullname: Swamy, Ravi organization: Centre for Perinatal Neuroscience, Imperial College London, London, UK – sequence: 6 givenname: Paul surname: Bassett fullname: Bassett, Paul organization: Statsconsultancy, Amersham, UK – sequence: 7 givenname: Josephine surname: Mendoza fullname: Mendoza, Josephine organization: Centre for Perinatal Neuroscience, Imperial College London, London, UK – sequence: 8 givenname: Gaurav surname: Atreja fullname: Atreja, Gaurav organization: Neonatal Unit, Imperial College Healthcare NHS Trust, London, UK – sequence: 9 givenname: Ujwal surname: Kariholu fullname: Kariholu, Ujwal organization: Neonatal Unit, Imperial College Healthcare NHS Trust, London, UK – sequence: 10 givenname: Santosh surname: Pattnayak fullname: Pattnayak, Santosh organization: Oliver Fisher Neonatal Unit, Medway NHS Foundation Trust, Kent, UK – sequence: 11 givenname: Palaniappan surname: Sashikumar fullname: Sashikumar, Palaniappan organization: Oliver Fisher Neonatal Unit, Medway NHS Foundation Trust, Kent, UK – sequence: 12 givenname: Helen surname: Harizaj fullname: Harizaj, Helen organization: Oliver Fisher Neonatal Unit, Medway NHS Foundation Trust, Kent, UK – sequence: 13 givenname: Martin surname: Mitchell fullname: Mitchell, Martin organization: Oliver Fisher Neonatal Unit, Medway NHS Foundation Trust, Kent, UK – sequence: 14 givenname: Vijayakumar surname: Ganesh fullname: Ganesh, Vijayakumar organization: Oliver Fisher Neonatal Unit, Medway NHS Foundation Trust, Kent, UK – sequence: 15 givenname: Sundeep surname: Harigopal fullname: Harigopal, Sundeep organization: Neonatal Unit, Royal Victoria Infirmary, Newcastle, UK – sequence: 16 givenname: Jennifer surname: Dixon fullname: Dixon, Jennifer organization: Neonatal Unit, Royal Victoria Infirmary, Newcastle, UK – sequence: 17 givenname: Philip surname: English fullname: English, Philip organization: Neonatal Unit, Royal Victoria Infirmary, Newcastle, UK – sequence: 18 givenname: Paul surname: Clarke fullname: Clarke, Paul organization: Neonatal Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK – sequence: 19 givenname: Priya surname: Muthukumar fullname: Muthukumar, Priya organization: Neonatal Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK – sequence: 20 givenname: Prakash surname: Satodia fullname: Satodia, Prakash organization: Neonatal Unit, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK – sequence: 21 givenname: Sarah surname: Wayte fullname: Wayte, Sarah organization: Neonatal Unit, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK – sequence: 22 givenname: Laurence J surname: Abernethy fullname: Abernethy, Laurence J organization: Neonatal Unit, Liverpool Women's NHS Foundation Trust, Liverpool, UK – sequence: 23 givenname: Kiran surname: Yajamanyam fullname: Yajamanyam, Kiran organization: Neonatal Unit, Liverpool Women's NHS Foundation Trust, Liverpool, UK – sequence: 24 givenname: Alan surname: Bainbridge fullname: Bainbridge, Alan organization: Neonatal Unit, University College London Hospitals NHS Foundation Trust, London, UK – sequence: 25 givenname: David surname: Price fullname: Price, David organization: Neonatal Unit, University College London Hospitals NHS Foundation Trust, London, UK – sequence: 26 givenname: Angela surname: Huertas fullname: Huertas, Angela organization: Neonatal Unit, University College London Hospitals NHS Foundation Trust, London, UK – sequence: 27 givenname: David J surname: Sharp fullname: Sharp, David J organization: Computational, Cognitive and Clinical Neuroimaging Laboratory, Imperial College London, London, UK – sequence: 28 givenname: Vaneet surname: Kalra fullname: Kalra, Vaneet organization: Neonatal-Perinatal Medicine, Wayne State University, Detroit, MI, USA – sequence: 29 givenname: Sanjay surname: Chawla fullname: Chawla, Sanjay organization: Neonatal-Perinatal Medicine, Wayne State University, Detroit, MI, USA – sequence: 30 givenname: Seetha surname: Shankaran fullname: Shankaran, Seetha organization: Neonatal-Perinatal Medicine, Wayne State University, Detroit, MI, USA – sequence: 31 givenname: Sudhin surname: Thayyil fullname: Thayyil, Sudhin email: s.thayyil@imperial.ac.uk organization: Centre for Perinatal Neuroscience, Imperial College London, London, UK – sequence: 32 givenname: Peter J surname: Lally fullname: Lally, Peter J – sequence: 33 givenname: Paolo surname: Montaldo fullname: Montaldo, Paolo – sequence: 34 givenname: Vânia surname: Oliveira fullname: Oliveira, Vânia – sequence: 35 givenname: Aung surname: Soe fullname: Soe, Aung – sequence: 36 givenname: Ravi surname: Swamy fullname: Swamy, Ravi – sequence: 37 givenname: Paul surname: Bassett fullname: Bassett, Paul – sequence: 38 givenname: Josephine surname: Mendoza fullname: Mendoza, Josephine – sequence: 39 givenname: Gaurav surname: Atreja fullname: Atreja, Gaurav – sequence: 40 givenname: Ujwal surname: Kariholu fullname: Kariholu, Ujwal – sequence: 41 givenname: Santosh surname: Pattnayak fullname: Pattnayak, Santosh – sequence: 42 givenname: Palaniappan surname: Sashikumar fullname: Sashikumar, Palaniappan – sequence: 43 givenname: Helen surname: Harizaj fullname: Harizaj, Helen – sequence: 44 givenname: Martin surname: Mitchell fullname: Mitchell, Martin – sequence: 45 givenname: Vijayakumar surname: Ganesh fullname: Ganesh, Vijayakumar – sequence: 46 givenname: Sundeeep surname: Harigopal fullname: Harigopal, Sundeeep – sequence: 47 givenname: Jennifer surname: Dixon fullname: Dixon, Jennifer – sequence: 48 givenname: Philip surname: English fullname: English, Philip – sequence: 49 givenname: Paul surname: Clarke fullname: Clarke, Paul – sequence: 50 givenname: Priya surname: Muthukumar fullname: Muthukumar, Priya – sequence: 51 givenname: Prakash surname: Satodia fullname: Satodia, Prakash – sequence: 52 givenname: Sarah surname: Wayte fullname: Wayte, Sarah – sequence: 53 givenname: Laurence J surname: Abernethy fullname: Abernethy, Laurence J – sequence: 54 givenname: Kiran surname: Yajamanyam fullname: Yajamanyam, Kiran – sequence: 55 givenname: Alan surname: Bainbridge fullname: Bainbridge, Alan – sequence: 56 givenname: David surname: Price fullname: Price, David – sequence: 57 givenname: Angela surname: Huertas fullname: Huertas, Angela – sequence: 58 givenname: David J surname: Sharp fullname: Sharp, David J – sequence: 59 givenname: Vaneet surname: Kalra fullname: Kalra, Vaneet – sequence: 60 givenname: Sanjay surname: Chawla fullname: Chawla, Sanjay – sequence: 61 givenname: Seetha surname: Shankaran fullname: Shankaran, Seetha – sequence: 62 givenname: Sudhin surname: Thayyil fullname: Thayyil, Sudhin |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30447969$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNksuOFCEUhitmjHPRR9CQuBkXrVBAXTRqzMRbMsaFsycUnJqirYIaoDqpN_FxpbrbjvZmXEHg_79z4D_n2Yl1FrLsKcEvCSbFqx-ElWzFWJ5fkuoFxTTnq_pBdrY_LvjJYZ_np9l5CGuMc8Iq8ig7pZixsi7qs-zXN3lrIRqFPARnpVWAwggqeheUG2ckQ4AQBrARuRY1XhqLjF1PPl21ETwanAYvI6BuHl3swA9GJgWykHBR9ggSc-xk70YZu_k1kmhM8KWG2QAapj5VT3gPSLnO-YhCnPT8OHvYyj7Ak_16kd18-nhz9WV1_f3z16sP1ytVEB5XupYVxxUlkmjOlZZlQxWlDa3KUldQtU3elmXOC6CkYEzWFValLinRhDSE04vs3Q47Ts0AetuI7MXozSD9LJw04t8bazpx6zaiyGvCeJUAl3uAd3cThCgGExT0vUwfMAWRE8oLWlCOk_T5kXTtJm_T65KKc8wZqxfVs787OrTyJ7Mk4DuBSt8YPLQHCcFimQ2xnQ2xBC9IJbazIRbfmyOfMlFG45aHmf5e9_udG1IYGwNeBGWWaLXxKUqhnbmX8PaIoHpjjZL9T5j_w_8buWbqww |
| CitedBy_id | crossref_primary_10_3389_fped_2022_925951 crossref_primary_10_1038_s41390_020_0827_4 crossref_primary_10_1016_j_semperi_2025_152131 crossref_primary_10_1136_archdischild_2024_327107 crossref_primary_10_1038_s41390_025_04058_1 crossref_primary_10_1038_s41390_024_03032_7 crossref_primary_10_1007_s00247_021_04983_3 crossref_primary_10_1038_s41390_024_03537_1 crossref_primary_10_1186_s12887_024_04773_4 crossref_primary_10_1542_peds_2020_048678 crossref_primary_10_1016_j_jpeds_2021_08_011 crossref_primary_10_1542_peds_2020_022962 crossref_primary_10_3389_fped_2022_1068380 crossref_primary_10_1016_j_clp_2019_02_008 crossref_primary_10_3389_fped_2020_00299 crossref_primary_10_1007_s00247_023_05680_z crossref_primary_10_1053_j_sult_2021_07_003 crossref_primary_10_1080_14767058_2025_2498547 crossref_primary_10_1016_j_jpeds_2024_114268 crossref_primary_10_1038_s41372_021_01233_0 crossref_primary_10_1016_j_clinph_2021_05_031 crossref_primary_10_1038_s41390_023_02679_y crossref_primary_10_1177_0271678X231162174 crossref_primary_10_1016_j_nicl_2021_102835 crossref_primary_10_1016_j_siny_2021_101257 crossref_primary_10_1016_j_pediatrneurol_2020_08_014 crossref_primary_10_3389_fneur_2020_00393 crossref_primary_10_1016_j_clp_2022_05_007 crossref_primary_10_3389_fped_2022_933962 crossref_primary_10_1016_j_semperi_2025_152125 crossref_primary_10_1016_j_pediatrneurol_2025_01_021 crossref_primary_10_1016_j_semperi_2025_152126 crossref_primary_10_1016_S1474_4422_19_30116_4 crossref_primary_10_4103_1673_5374_290875 crossref_primary_10_1016_j_jpeds_2019_11_030 crossref_primary_10_3390_cells11162602 crossref_primary_10_4103_1673_5374_330616 crossref_primary_10_1016_j_ab_2023_115227 crossref_primary_10_1055_s_0040_1716341 crossref_primary_10_1016_j_pedneo_2025_01_014 crossref_primary_10_1038_s41390_022_02126_4 crossref_primary_10_1038_s41392_023_01399_3 crossref_primary_10_1016_j_jpeds_2023_113879 crossref_primary_10_1016_j_ejpn_2021_02_003 crossref_primary_10_1038_s41598_022_11870_w crossref_primary_10_1097_CCM_0000000000005251 crossref_primary_10_3389_fneur_2020_00883 crossref_primary_10_1016_j_yacr_2025_05_009 crossref_primary_10_3389_fped_2024_1403671 crossref_primary_10_1093_bjr_tqae048 crossref_primary_10_3390_biomedicines10050937 crossref_primary_10_1002_jmri_29709 crossref_primary_10_1016_j_resuscitation_2025_110700 crossref_primary_10_1038_s41390_025_03986_2 crossref_primary_10_1016_j_pcl_2025_05_006 crossref_primary_10_1038_s41372_021_01156_w crossref_primary_10_1001_jamanetworkopen_2023_12152 crossref_primary_10_1080_20469047_2019_1596586 crossref_primary_10_1007_s12098_022_04187_z crossref_primary_10_3389_fneur_2025_1565749 crossref_primary_10_1038_s41372_021_01302_4 crossref_primary_10_1016_j_ymgme_2023_107584 crossref_primary_10_1016_j_earlhumdev_2021_105479 crossref_primary_10_1016_j_ebiom_2019_08_034 crossref_primary_10_1016_j_nbd_2021_105316 crossref_primary_10_1016_S1474_4422_19_30111_5 crossref_primary_10_1002_mrm_28385 crossref_primary_10_1016_j_jpeds_2021_07_003 crossref_primary_10_1136_archdischild_2020_321164 crossref_primary_10_1016_j_jpeds_2024_113933 crossref_primary_10_1080_02699052_2022_2034041 crossref_primary_10_3390_antiox10091344 crossref_primary_10_1038_s41372_022_01401_w crossref_primary_10_1016_j_ultras_2024_107465 crossref_primary_10_1212_WNL_0000000000013297 crossref_primary_10_1038_s41390_024_03261_w crossref_primary_10_1038_s41372_024_02172_2 crossref_primary_10_1055_a_2540_2956 crossref_primary_10_1136_bmjopen_2025_107083 crossref_primary_10_1038_s41390_021_01626_z crossref_primary_10_3390_app14219651 crossref_primary_10_1055_a_1889_8544 crossref_primary_10_1007_s00431_022_04778_0 crossref_primary_10_1136_archdischild_2023_326747 crossref_primary_10_1016_j_pediatrneurol_2021_10_005 crossref_primary_10_1136_bmjopen_2020_043852 crossref_primary_10_4103_NRR_NRR_D_24_00970 crossref_primary_10_1007_s00234_021_02821_9 crossref_primary_10_1016_j_semperi_2024_151929 crossref_primary_10_1136_archdischild_2024_326960 crossref_primary_10_1259_bjr_20210128 crossref_primary_10_1038_s41390_023_02510_8 crossref_primary_10_3389_fped_2023_1268237 crossref_primary_10_3389_fped_2020_576489 crossref_primary_10_3390_children10081295 crossref_primary_10_1097_MOP_0000000000001299 crossref_primary_10_3390_cells9081871 crossref_primary_10_1177_19345798251350998 crossref_primary_10_1089_ther_2018_0052 crossref_primary_10_1016_j_clp_2024_04_005 crossref_primary_10_1016_j_jcyt_2020_10_005 crossref_primary_10_1016_j_crad_2020_12_026 crossref_primary_10_1016_j_semperi_2024_151930 crossref_primary_10_1016_j_lansea_2023_100284 crossref_primary_10_1371_journal_pone_0243255 crossref_primary_10_3389_fnins_2023_1234049 crossref_primary_10_1038_s41390_019_0729_5 crossref_primary_10_1038_s41390_021_01803_0 crossref_primary_10_1016_j_jpeds_2024_114086 crossref_primary_10_1016_j_clp_2025_02_010 crossref_primary_10_1038_s41372_019_0551_2 crossref_primary_10_3389_fped_2021_787804 crossref_primary_10_1186_s12967_019_2119_5 crossref_primary_10_3390_diagnostics12030645 crossref_primary_10_1136_bmjpo_2025_003530 crossref_primary_10_1097_MAT_0000000000001525 crossref_primary_10_1038_s41390_025_04336_y crossref_primary_10_1136_archdischild_2018_315711 crossref_primary_10_1038_s41390_022_02212_7 crossref_primary_10_1016_j_clp_2025_02_004 crossref_primary_10_1016_j_ebiom_2023_104673 crossref_primary_10_1016_j_cppeds_2019_07_001 crossref_primary_10_1186_s40001_022_00954_y crossref_primary_10_1038_s41390_020_0859_9 crossref_primary_10_1089_brain_2021_0058 crossref_primary_10_1016_j_siny_2021_101271 crossref_primary_10_1159_000530411 crossref_primary_10_1001_jamanetworkopen_2024_9119 crossref_primary_10_3389_fped_2021_653676 crossref_primary_10_1159_000505519 crossref_primary_10_1007_s00247_021_04974_4 crossref_primary_10_1016_j_nicl_2021_102582 crossref_primary_10_1038_s41372_020_00828_3 crossref_primary_10_1007_s12028_023_01690_9 crossref_primary_10_1016_j_siny_2021_101304 crossref_primary_10_1016_j_jpeds_2020_11_015 crossref_primary_10_1038_s41390_021_01656_7 crossref_primary_10_1007_s40124_023_00289_0 crossref_primary_10_1016_j_ebiom_2020_102663 crossref_primary_10_55095_CSPediatrie2025_003 crossref_primary_10_1038_s41390_020_1024_1 crossref_primary_10_1016_j_jpeds_2021_04_003 |
| Cites_doi | 10.1016/S0140-6736(05)71048-5 10.1148/radiol.13130531 10.1016/j.mri.2017.06.001 10.1001/jama.2017.7218 10.1001/jama.2017.14972 10.1001/archpediatrics.2012.284 10.1136/bmjopen-2015-008912 10.1136/archdischild-2011-301524 10.1542/peds.103.6.1263 10.1136/archdischild-2016-310514 10.1542/peds.2009-1046 10.2174/157339631001140408120336 10.1542/peds.2012-1297 10.1016/j.clp.2018.01.010 10.1016/S1474-4422(15)00347-6 10.1136/archdischild-2017-313320 10.1038/jp.2017.14 10.1186/s13063-017-2165-3 10.1159/000472709 10.1016/S1474-4422(09)70295-9 10.1016/j.neuroimage.2017.08.047 10.1002/ana.410310104 10.1001/jama.2014.16058 10.2174/157339631001140408120613 10.1016/j.jpeds.2017.08.031 10.1212/01.wnl.0000291557.62706.d3 10.1007/s00234-013-1202-5 10.1159/000486820 10.1148/radiol.2018172083 |
| ContentType | Journal Article |
| Contributor | Mitchell, Martin Abernethy, Laurence J Bassett, Paul Clarke, Paul Mendoza, Josephine Pattnayak, Santosh Satodia, Prakash Harigopal, Sundeeep Muthukumar, Priya Swamy, Ravi Huertas, Angela Sashikumar, Palaniappan Yajamanyam, Kiran Harizaj, Helen Kalra, Vaneet Kariholu, Ujwal Bainbridge, Alan Thayyil, Sudhin Ganesh, Vijayakumar Dixon, Jennifer Atreja, Gaurav Chawla, Sanjay Sharp, David J Shankaran, Seetha Oliveira, Vânia Wayte, Sarah Soe, Aung Price, David Montaldo, Paolo Lally, Peter J English, Philip |
| Contributor_xml | – sequence: 1 givenname: Peter J surname: Lally fullname: Lally, Peter J – sequence: 2 givenname: Paolo surname: Montaldo fullname: Montaldo, Paolo – sequence: 3 givenname: Vânia surname: Oliveira fullname: Oliveira, Vânia – sequence: 4 givenname: Aung surname: Soe fullname: Soe, Aung – sequence: 5 givenname: Ravi surname: Swamy fullname: Swamy, Ravi – sequence: 6 givenname: Paul surname: Bassett fullname: Bassett, Paul – sequence: 7 givenname: Josephine surname: Mendoza fullname: Mendoza, Josephine – sequence: 8 givenname: Gaurav surname: Atreja fullname: Atreja, Gaurav – sequence: 9 givenname: Ujwal surname: Kariholu fullname: Kariholu, Ujwal – sequence: 10 givenname: Santosh surname: Pattnayak fullname: Pattnayak, Santosh – sequence: 11 givenname: Palaniappan surname: Sashikumar fullname: Sashikumar, Palaniappan – sequence: 12 givenname: Helen surname: Harizaj fullname: Harizaj, Helen – sequence: 13 givenname: Martin surname: Mitchell fullname: Mitchell, Martin – sequence: 14 givenname: Vijayakumar surname: Ganesh fullname: Ganesh, Vijayakumar – sequence: 15 givenname: Sundeeep surname: Harigopal fullname: Harigopal, Sundeeep – sequence: 16 givenname: Jennifer surname: Dixon fullname: Dixon, Jennifer – sequence: 17 givenname: Philip surname: English fullname: English, Philip – sequence: 18 givenname: Paul surname: Clarke fullname: Clarke, Paul – sequence: 19 givenname: Priya surname: Muthukumar fullname: Muthukumar, Priya – sequence: 20 givenname: Prakash surname: Satodia fullname: Satodia, Prakash – sequence: 21 givenname: Sarah surname: Wayte fullname: Wayte, Sarah – sequence: 22 givenname: Laurence J surname: Abernethy fullname: Abernethy, Laurence J – sequence: 23 givenname: Kiran surname: Yajamanyam fullname: Yajamanyam, Kiran – sequence: 24 givenname: Alan surname: Bainbridge fullname: Bainbridge, Alan – sequence: 25 givenname: David surname: Price fullname: Price, David – sequence: 26 givenname: Angela surname: Huertas fullname: Huertas, Angela – sequence: 27 givenname: David J surname: Sharp fullname: Sharp, David J – sequence: 28 givenname: Vaneet surname: Kalra fullname: Kalra, Vaneet – sequence: 29 givenname: Sanjay surname: Chawla fullname: Chawla, Sanjay – sequence: 30 givenname: Seetha surname: Shankaran fullname: Shankaran, Seetha – sequence: 31 givenname: Sudhin surname: Thayyil fullname: Thayyil, Sudhin |
| Copyright | 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. Copyright Elsevier Limited Jan 2019 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2019 |
| Copyright_xml | – notice: 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license – notice: Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. – notice: Copyright Elsevier Limited Jan 2019 – notice: 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2019 |
| CorporateAuthor | MARBLE consortium |
| CorporateAuthor_xml | – name: MARBLE consortium |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TK 7X7 7XB 88E 88G 8AO 8C2 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ K9. KB0 M0S M1P M2M NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PSYQQ Q9U 7X8 5PM |
| DOI | 10.1016/S1474-4422(18)30325-9 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Neurosciences Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Pharma Collection Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Psychology Database Nursing & Allied Health Premium ProQuest Databases ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE ProQuest One Psychology MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-4465 |
| EndPage | 45 |
| ExternalDocumentID | PMC6291458 30447969 10_1016_S1474_4422_18_30325_9 S1474442218303259 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United Kingdom--UK United States--US |
| GeographicLocations_xml | – name: United Kingdom--UK – name: United States--US |
| GrantInformation | National Institute for Health Research UK. |
| GrantInformation_xml | – fundername: Department of Health grantid: NIHR300118 – fundername: Department of Health grantid: NIHR/CS/010/022 – fundername: Department of Health grantid: ICA-CDRF-2016-02-071 – fundername: Department of Health grantid: HCS DRF-2014-05-013 |
| GroupedDBID | --- --K --M -RU .1- .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 8AO 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABIVO ABJNI ABMAC ABMZM ABOCM ABTEW ABUWG ABWVN ACGFS ACIEU ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGHFR AGWIK AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP AXJTR AZQEC BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ HF~ HMCUK HVGLF HZ~ IHE J1W JCF KOM M1P M2M M41 MO0 N9A NAPCQ O-L O9- OP~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PSYQQ ROL RPZ SDG SEL SES SPCBC SSH SSN SSZ T5K TLN UHS UKHRP UV1 WOW XBR Z5R ~HD 3V. 6I. AACTN AADPK AAFTH ABLVK ABYKQ AFKWA AJBFU AJOXV AMFUW RIG SDF ZA5 9DU AAYXX AFFHD CITATION AFCTW AGCQF AGRNS ALIPV CGR CUY CVF ECM EIF NPM 7TK 7XB 8FK K9. PKEHL PQEST PQUKI Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c615t-d9a850831a1d55cda7b3c33b3877d8e8fb2f77256e31644a980c7d731d11b153 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 170 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000453007700021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1474-4422 1474-4465 |
| IngestDate | Tue Nov 04 01:55:54 EST 2025 Wed Oct 01 09:44:34 EDT 2025 Sun Nov 30 05:19:29 EST 2025 Mon Jul 21 06:08:14 EDT 2025 Sat Nov 29 07:00:56 EST 2025 Tue Nov 18 21:29:37 EST 2025 Fri Feb 23 02:43:08 EST 2024 Tue Oct 14 19:33:15 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | This is an open access article under the CC BY license. Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c615t-d9a850831a1d55cda7b3c33b3877d8e8fb2f77256e31644a980c7d731d11b153 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Members listed in the appendix Contributed equally |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC6291458 |
| PMID | 30447969 |
| PQID | 2155054490 |
| PQPubID | 26255 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6291458 proquest_miscellaneous_2135636350 proquest_journals_2155054490 pubmed_primary_30447969 crossref_primary_10_1016_S1474_4422_18_30325_9 crossref_citationtrail_10_1016_S1474_4422_18_30325_9 elsevier_sciencedirect_doi_10_1016_S1474_4422_18_30325_9 elsevier_clinicalkey_doi_10_1016_S1474_4422_18_30325_9 |
| PublicationCentury | 2000 |
| PublicationDate | January 2019 2019-01-00 20190101 |
| PublicationDateYYYYMMDD | 2019-01-01 |
| PublicationDate_xml | – month: 01 year: 2019 text: January 2019 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Lancet neurology |
| PublicationTitleAlternate | Lancet Neurol |
| PublicationYear | 2019 |
| Publisher | Elsevier Ltd Elsevier Limited Lancet Pub. Group |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited – name: Lancet Pub. Group |
| References | Alderliesten, de Vries, Staats (bib17) 2017; 102 Sijens, Wischniowsky, Ter Horst (bib16) 2017; 42 Laptook, Shankaran, Tyson (bib25) 2017; 318 Azzopardi, Robertson, Bainbridge (bib31) 2016; 15 Chandrasekaran, Chaban, Montaldo, Thayyil (bib19) 2017; 37 Williams, Gunn, Mallard, Gluckman (bib29) 1992; 31 Berger, Brekke, Wideroe, Morken (bib4) 2017; 39 Jacobs, Berg, Hunt, Tarnow-Mordi, Inder, Davis (bib2) 2013; 1 De Stefano, Filippi, Miller (bib9) 2007; 69 Montaldo P, Lally PJ, Kariholu U, et al. Therapeutic hypothermia in mild neonatal encephalopathy: a systematic review and meta-analysis. Pediatric Academic Society Meeting; Toronto; May 5–8, 2018. 2939840. van Laerhoven, de Haan, Offringa, Post, van der Lee (bib8) 2013; 131 Shibasaki, Aida, Morisaki, Tomiyasu, Nishi, Toyoshima (bib15) 2018; 288 Shankaran, Barnes, Hintz (bib20) 2012; 97 Cheong, Coleman, Hunt (bib21) 2012; 166 Thayyil, Oliveira, Lally (bib26) 2017; 18 Oz, Alger, Barker (bib10) 2014; 270 Lawn, Zupan (bib1) 2005; 365 Ancora, Testa, Grandi (bib18) 2013; 55 Parikh, Juul (bib3) 2018; 192 Rutherford, Ramenghi, Edwards (bib13) 2010; 9 Fortin, Parker, Tunc (bib27) 2017; 161 Chau, Poskitt, Dunham, Hendson, Miller (bib5) 2014; 10 Thayyil, Chandrasekaran, Taylor (bib7) 2010; 125 al Naqeeb, Edwards, Cowan, Azzopardi (bib14) 1999; 103 Robertson, Thayyil, Cady, Raivich (bib6) 2014; 10 Shankaran, Laptook, Pappas (bib24) 2017; 318 Shankaran, Laptook, Pappas (bib30) 2014; 312 Juul, Comstock, Heagerty (bib28) 2018; 113 Natarajan, Laptook, Shankaran (bib12) 2018; 45 Lally, Pauliah, Montaldo (bib11) 2015; 5 Oliveira, Singhvi, Montaldo (bib22) 2018; 103 Juul (10.1016/S1474-4422(18)30325-9_bib28) 2018; 113 Laptook (10.1016/S1474-4422(18)30325-9_bib25) 2017; 318 Parikh (10.1016/S1474-4422(18)30325-9_bib3) 2018; 192 Natarajan (10.1016/S1474-4422(18)30325-9_bib12) 2018; 45 Jacobs (10.1016/S1474-4422(18)30325-9_bib2) 2013; 1 Williams (10.1016/S1474-4422(18)30325-9_bib29) 1992; 31 Chau (10.1016/S1474-4422(18)30325-9_bib5) 2014; 10 Alderliesten (10.1016/S1474-4422(18)30325-9_bib17) 2017; 102 Chandrasekaran (10.1016/S1474-4422(18)30325-9_bib19) 2017; 37 Cheong (10.1016/S1474-4422(18)30325-9_bib21) 2012; 166 Oliveira (10.1016/S1474-4422(18)30325-9_bib22) 2018; 103 Sijens (10.1016/S1474-4422(18)30325-9_bib16) 2017; 42 Shankaran (10.1016/S1474-4422(18)30325-9_bib30) 2014; 312 Shankaran (10.1016/S1474-4422(18)30325-9_bib24) 2017; 318 Oz (10.1016/S1474-4422(18)30325-9_bib10) 2014; 270 10.1016/S1474-4422(18)30325-9_bib23 Lally (10.1016/S1474-4422(18)30325-9_bib11) 2015; 5 Ancora (10.1016/S1474-4422(18)30325-9_bib18) 2013; 55 Robertson (10.1016/S1474-4422(18)30325-9_bib6) 2014; 10 Shibasaki (10.1016/S1474-4422(18)30325-9_bib15) 2018; 288 Fortin (10.1016/S1474-4422(18)30325-9_bib27) 2017; 161 Azzopardi (10.1016/S1474-4422(18)30325-9_bib31) 2016; 15 van Laerhoven (10.1016/S1474-4422(18)30325-9_bib8) 2013; 131 Rutherford (10.1016/S1474-4422(18)30325-9_bib13) 2010; 9 Lawn (10.1016/S1474-4422(18)30325-9_bib1) 2005; 365 Berger (10.1016/S1474-4422(18)30325-9_bib4) 2017; 39 Thayyil (10.1016/S1474-4422(18)30325-9_bib26) 2017; 18 De Stefano (10.1016/S1474-4422(18)30325-9_bib9) 2007; 69 al Naqeeb (10.1016/S1474-4422(18)30325-9_bib14) 1999; 103 Shankaran (10.1016/S1474-4422(18)30325-9_bib20) 2012; 97 Thayyil (10.1016/S1474-4422(18)30325-9_bib7) 2010; 125 30447972 - Lancet Neurol. 2019 Jan;18(1):21-22. doi: 10.1016/S1474-4422(18)30370-3. 30981317 - Lancet Neurol. 2019 May;18(5):423-424. doi: 10.1016/S1474-4422(19)30116-4. 30981318 - Lancet Neurol. 2019 May;18(5):423. doi: 10.1016/S1474-4422(19)30111-5. |
| References_xml | – volume: 288 start-page: 840 year: 2018 end-page: 848 ident: bib15 article-title: Changes in brain metabolite concentrations after neonatal hypoxic-ischemic encephalopathy publication-title: Radiology – volume: 113 start-page: 331 year: 2018 end-page: 338 ident: bib28 article-title: High-Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL): A Randomized Controlled Trial - Background, Aims, and Study Protocol publication-title: Neonatology – volume: 270 start-page: 658 year: 2014 end-page: 679 ident: bib10 article-title: Clinical proton MR spectroscopy in central nervous system disorders publication-title: Radiology – volume: 103 start-page: 1263 year: 1999 end-page: 1271 ident: bib14 article-title: Assessment of neonatal encephalopathy by amplitude-integrated electroencephalography publication-title: Pediatrics – volume: 39 start-page: 36 year: 2017 end-page: 48 ident: bib4 article-title: Neuroprotective treatments after perinatal hypoxic-ischemic brain injury evaluated with magnetic resonance spectroscopy publication-title: Dev Neurosci – volume: 365 start-page: 891 year: 2005 end-page: 900 ident: bib1 article-title: 4 million neonatal deaths: When? Where? Why? publication-title: Lancet – volume: 5 start-page: e008912 year: 2015 ident: bib11 article-title: Magnetic resonance biomarkers in neonatal encephalopathy (MARBLE): a prospective multicountry study publication-title: BMJ Open – volume: 166 start-page: 634 year: 2012 end-page: 640 ident: bib21 article-title: Prognostic utility of magnetic resonance imaging in neonatal hypoxic-ischemic encephalopathy: substudy of a randomized trial publication-title: Arch Pediatr Adolesc Med – volume: 103 start-page: F388 year: 2018 end-page: F390 ident: bib22 article-title: Therapeutic hypothermia in mild neonatal encephalopathy: a national survey of practice in the UK publication-title: Arch Dis Child Fetal Neonatal Ed – volume: 192 start-page: 22 year: 2018 end-page: 32 ident: bib3 article-title: Neuroprotective strategies in neonatal brain injury publication-title: J Pediatr – volume: 18 start-page: 432 year: 2017 ident: bib26 article-title: Hypothermia for encephalopathy in low and middle-income countries (HELIX): study protocol for a randomised controlled trial publication-title: Trials – volume: 131 start-page: 88 year: 2013 end-page: 98 ident: bib8 article-title: Prognostic tests in term neonates with hypoxic-ischemic encephalopathy: a systematic review publication-title: Pediatrics – volume: 15 start-page: 145 year: 2016 end-page: 153 ident: bib31 article-title: Moderate hypothermia within 6 h of birth plus inhaled xenon versus moderate hypothermia alone after birth asphyxia (TOBY-Xe): a proof-of-concept, open-label, randomised controlled trial publication-title: Lancet Neurol – volume: 42 start-page: 82 year: 2017 end-page: 87 ident: bib16 article-title: The prognostic value of proton magnetic resonance spectroscopy in term newborns treated with therapeutic hypothermia following asphyxia publication-title: Magn Reson Imaging – reference: Montaldo P, Lally PJ, Kariholu U, et al. Therapeutic hypothermia in mild neonatal encephalopathy: a systematic review and meta-analysis. Pediatric Academic Society Meeting; Toronto; May 5–8, 2018. 2939840. – volume: 102 start-page: F147 year: 2017 end-page: F152 ident: bib17 article-title: MRI and spectroscopy in (near) term neonates with perinatal asphyxia and therapeutic hypothermia publication-title: Arch Dis Child Fetal Neonatal Ed – volume: 318 start-page: 1550 year: 2017 end-page: 1560 ident: bib25 article-title: Effect of therapeutic hypothermia initiated after 6 hours of age on death or disability among newborns with hypoxic-ischemic encephalopathy: a randomized clinical trial publication-title: JAMA – volume: 161 start-page: 149 year: 2017 end-page: 170 ident: bib27 article-title: Harmonization of multi-site diffusion tensor imaging data publication-title: Neuroimage – volume: 318 start-page: 57 year: 2017 end-page: 67 ident: bib24 article-title: Effect of depth and duration of cooling on death or disability at age 18 months among neonates with hypoxic-ischemic encephalopathy: a randomized clinical trial publication-title: JAMA – volume: 312 start-page: 2629 year: 2014 end-page: 2639 ident: bib30 article-title: Effect of depth and duration of cooling on deaths in the NICU among neonates with hypoxic ischemic encephalopathy: a randomized clinical trial publication-title: JAMA – volume: 125 start-page: e382 year: 2010 end-page: e395 ident: bib7 article-title: Cerebral magnetic resonance biomarkers in neonatal encephalopathy: a meta-analysis publication-title: Pediatrics – volume: 45 start-page: 241 year: 2018 end-page: 255 ident: bib12 article-title: Therapeutic hypothermia: how can we optimize this therapy to further improve outcomes? publication-title: Clin Perinatol – volume: 10 start-page: 28 year: 2014 end-page: 36 ident: bib5 article-title: Magnetic resonance imaging in the encephalopathic term newborn publication-title: Curr Pediatr Rev – volume: 10 start-page: 37 year: 2014 end-page: 47 ident: bib6 article-title: Magnetic resonance spectroscopy biomarkers in term perinatal asphyxial encephalopathy: from neuropathological correlates to future clinical applications publication-title: Curr Pediatr Rev – volume: 31 start-page: 14 year: 1992 end-page: 21 ident: bib29 article-title: Outcome after ischemia in the developing sheep brain: an electroencephalographic and histological study publication-title: Ann Neurol – volume: 69 start-page: 1942 year: 2007 end-page: 1952 ident: bib9 article-title: Guidelines for using proton MR spectroscopy in multicenter clinical MS studies publication-title: Neurology – volume: 1 year: 2013 ident: bib2 article-title: Cooling for newborns with hypoxic ischaemic encephalopathy publication-title: Cochrane Database Syst Rev – volume: 37 start-page: 684 year: 2017 end-page: 689 ident: bib19 article-title: Predictive value of amplitude-integrated EEG (aEEG) after rescue hypothermic neuroprotection for hypoxic ischemic encephalopathy: a meta-analysis publication-title: J Perinatol – volume: 9 start-page: 39 year: 2010 end-page: 45 ident: bib13 article-title: Assessment of brain tissue injury after moderate hypothermia in neonates with hypoxic-ischaemic encephalopathy: a nested substudy of a randomised controlled trial publication-title: Lancet Neurol – volume: 55 start-page: 1017 year: 2013 end-page: 1025 ident: bib18 article-title: Prognostic value of brain proton MR spectroscopy and diffusion tensor imaging in newborns with hypoxic-ischemic encephalopathy treated by brain cooling publication-title: Neuroradiology – volume: 97 start-page: F398 year: 2012 end-page: F404 ident: bib20 article-title: Brain injury following trial of hypothermia for neonatal hypoxic-ischaemic encephalopathy publication-title: Arch Dis Child Fetal Neonatal Ed – volume: 365 start-page: 891 year: 2005 ident: 10.1016/S1474-4422(18)30325-9_bib1 article-title: 4 million neonatal deaths: When? Where? Why? publication-title: Lancet doi: 10.1016/S0140-6736(05)71048-5 – volume: 270 start-page: 658 year: 2014 ident: 10.1016/S1474-4422(18)30325-9_bib10 article-title: Clinical proton MR spectroscopy in central nervous system disorders publication-title: Radiology doi: 10.1148/radiol.13130531 – volume: 42 start-page: 82 year: 2017 ident: 10.1016/S1474-4422(18)30325-9_bib16 article-title: The prognostic value of proton magnetic resonance spectroscopy in term newborns treated with therapeutic hypothermia following asphyxia publication-title: Magn Reson Imaging doi: 10.1016/j.mri.2017.06.001 – volume: 318 start-page: 57 year: 2017 ident: 10.1016/S1474-4422(18)30325-9_bib24 article-title: Effect of depth and duration of cooling on death or disability at age 18 months among neonates with hypoxic-ischemic encephalopathy: a randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2017.7218 – volume: 318 start-page: 1550 year: 2017 ident: 10.1016/S1474-4422(18)30325-9_bib25 article-title: Effect of therapeutic hypothermia initiated after 6 hours of age on death or disability among newborns with hypoxic-ischemic encephalopathy: a randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2017.14972 – volume: 166 start-page: 634 year: 2012 ident: 10.1016/S1474-4422(18)30325-9_bib21 article-title: Prognostic utility of magnetic resonance imaging in neonatal hypoxic-ischemic encephalopathy: substudy of a randomized trial publication-title: Arch Pediatr Adolesc Med doi: 10.1001/archpediatrics.2012.284 – volume: 5 start-page: e008912 year: 2015 ident: 10.1016/S1474-4422(18)30325-9_bib11 article-title: Magnetic resonance biomarkers in neonatal encephalopathy (MARBLE): a prospective multicountry study publication-title: BMJ Open doi: 10.1136/bmjopen-2015-008912 – volume: 97 start-page: F398 year: 2012 ident: 10.1016/S1474-4422(18)30325-9_bib20 article-title: Brain injury following trial of hypothermia for neonatal hypoxic-ischaemic encephalopathy publication-title: Arch Dis Child Fetal Neonatal Ed doi: 10.1136/archdischild-2011-301524 – volume: 103 start-page: 1263 year: 1999 ident: 10.1016/S1474-4422(18)30325-9_bib14 article-title: Assessment of neonatal encephalopathy by amplitude-integrated electroencephalography publication-title: Pediatrics doi: 10.1542/peds.103.6.1263 – volume: 102 start-page: F147 year: 2017 ident: 10.1016/S1474-4422(18)30325-9_bib17 article-title: MRI and spectroscopy in (near) term neonates with perinatal asphyxia and therapeutic hypothermia publication-title: Arch Dis Child Fetal Neonatal Ed doi: 10.1136/archdischild-2016-310514 – volume: 125 start-page: e382 year: 2010 ident: 10.1016/S1474-4422(18)30325-9_bib7 article-title: Cerebral magnetic resonance biomarkers in neonatal encephalopathy: a meta-analysis publication-title: Pediatrics doi: 10.1542/peds.2009-1046 – volume: 10 start-page: 28 year: 2014 ident: 10.1016/S1474-4422(18)30325-9_bib5 article-title: Magnetic resonance imaging in the encephalopathic term newborn publication-title: Curr Pediatr Rev doi: 10.2174/157339631001140408120336 – volume: 131 start-page: 88 year: 2013 ident: 10.1016/S1474-4422(18)30325-9_bib8 article-title: Prognostic tests in term neonates with hypoxic-ischemic encephalopathy: a systematic review publication-title: Pediatrics doi: 10.1542/peds.2012-1297 – volume: 45 start-page: 241 year: 2018 ident: 10.1016/S1474-4422(18)30325-9_bib12 article-title: Therapeutic hypothermia: how can we optimize this therapy to further improve outcomes? publication-title: Clin Perinatol doi: 10.1016/j.clp.2018.01.010 – volume: 15 start-page: 145 year: 2016 ident: 10.1016/S1474-4422(18)30325-9_bib31 article-title: Moderate hypothermia within 6 h of birth plus inhaled xenon versus moderate hypothermia alone after birth asphyxia (TOBY-Xe): a proof-of-concept, open-label, randomised controlled trial publication-title: Lancet Neurol doi: 10.1016/S1474-4422(15)00347-6 – volume: 103 start-page: F388 year: 2018 ident: 10.1016/S1474-4422(18)30325-9_bib22 article-title: Therapeutic hypothermia in mild neonatal encephalopathy: a national survey of practice in the UK publication-title: Arch Dis Child Fetal Neonatal Ed doi: 10.1136/archdischild-2017-313320 – volume: 37 start-page: 684 year: 2017 ident: 10.1016/S1474-4422(18)30325-9_bib19 article-title: Predictive value of amplitude-integrated EEG (aEEG) after rescue hypothermic neuroprotection for hypoxic ischemic encephalopathy: a meta-analysis publication-title: J Perinatol doi: 10.1038/jp.2017.14 – volume: 18 start-page: 432 year: 2017 ident: 10.1016/S1474-4422(18)30325-9_bib26 article-title: Hypothermia for encephalopathy in low and middle-income countries (HELIX): study protocol for a randomised controlled trial publication-title: Trials doi: 10.1186/s13063-017-2165-3 – volume: 39 start-page: 36 year: 2017 ident: 10.1016/S1474-4422(18)30325-9_bib4 article-title: Neuroprotective treatments after perinatal hypoxic-ischemic brain injury evaluated with magnetic resonance spectroscopy publication-title: Dev Neurosci doi: 10.1159/000472709 – volume: 9 start-page: 39 year: 2010 ident: 10.1016/S1474-4422(18)30325-9_bib13 article-title: Assessment of brain tissue injury after moderate hypothermia in neonates with hypoxic-ischaemic encephalopathy: a nested substudy of a randomised controlled trial publication-title: Lancet Neurol doi: 10.1016/S1474-4422(09)70295-9 – volume: 161 start-page: 149 year: 2017 ident: 10.1016/S1474-4422(18)30325-9_bib27 article-title: Harmonization of multi-site diffusion tensor imaging data publication-title: Neuroimage doi: 10.1016/j.neuroimage.2017.08.047 – volume: 31 start-page: 14 year: 1992 ident: 10.1016/S1474-4422(18)30325-9_bib29 article-title: Outcome after ischemia in the developing sheep brain: an electroencephalographic and histological study publication-title: Ann Neurol doi: 10.1002/ana.410310104 – volume: 312 start-page: 2629 year: 2014 ident: 10.1016/S1474-4422(18)30325-9_bib30 article-title: Effect of depth and duration of cooling on deaths in the NICU among neonates with hypoxic ischemic encephalopathy: a randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2014.16058 – volume: 10 start-page: 37 year: 2014 ident: 10.1016/S1474-4422(18)30325-9_bib6 article-title: Magnetic resonance spectroscopy biomarkers in term perinatal asphyxial encephalopathy: from neuropathological correlates to future clinical applications publication-title: Curr Pediatr Rev doi: 10.2174/157339631001140408120613 – ident: 10.1016/S1474-4422(18)30325-9_bib23 – volume: 1 year: 2013 ident: 10.1016/S1474-4422(18)30325-9_bib2 article-title: Cooling for newborns with hypoxic ischaemic encephalopathy publication-title: Cochrane Database Syst Rev – volume: 192 start-page: 22 year: 2018 ident: 10.1016/S1474-4422(18)30325-9_bib3 article-title: Neuroprotective strategies in neonatal brain injury publication-title: J Pediatr doi: 10.1016/j.jpeds.2017.08.031 – volume: 69 start-page: 1942 year: 2007 ident: 10.1016/S1474-4422(18)30325-9_bib9 article-title: Guidelines for using proton MR spectroscopy in multicenter clinical MS studies publication-title: Neurology doi: 10.1212/01.wnl.0000291557.62706.d3 – volume: 55 start-page: 1017 year: 2013 ident: 10.1016/S1474-4422(18)30325-9_bib18 article-title: Prognostic value of brain proton MR spectroscopy and diffusion tensor imaging in newborns with hypoxic-ischemic encephalopathy treated by brain cooling publication-title: Neuroradiology doi: 10.1007/s00234-013-1202-5 – volume: 113 start-page: 331 year: 2018 ident: 10.1016/S1474-4422(18)30325-9_bib28 article-title: High-Dose Erythropoietin for Asphyxia and Encephalopathy (HEAL): A Randomized Controlled Trial - Background, Aims, and Study Protocol publication-title: Neonatology doi: 10.1159/000486820 – volume: 288 start-page: 840 year: 2018 ident: 10.1016/S1474-4422(18)30325-9_bib15 article-title: Changes in brain metabolite concentrations after neonatal hypoxic-ischemic encephalopathy publication-title: Radiology doi: 10.1148/radiol.2018172083 – reference: 30981318 - Lancet Neurol. 2019 May;18(5):423. doi: 10.1016/S1474-4422(19)30111-5. – reference: 30447972 - Lancet Neurol. 2019 Jan;18(1):21-22. doi: 10.1016/S1474-4422(18)30370-3. – reference: 30981317 - Lancet Neurol. 2019 May;18(5):423-424. doi: 10.1016/S1474-4422(19)30116-4. |
| SSID | ssj0021481 |
| Score | 2.6246538 |
| Snippet | In neonatal encephalopathy, the clinical manifestations of injury can only be reliably assessed several years after an intervention, complicating early... Summary Background In neonatal encephalopathy, the clinical manifestations of injury can only be reliably assessed several years after an intervention,... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 35 |
| SubjectTerms | Accuracy Anisotropy Aspartic Acid - analogs & derivatives Aspartic Acid - metabolism Basal ganglia Biomarkers Brain - diagnostic imaging Brain - metabolism Brain injury Brain research Choline Clinical trials Cohort analysis Congenital defects Cortex Creatine EEG Encephalopathy Female Humans Hypothermia Hypothermia, Induced Hypoxia-Ischemia, Brain - diagnostic imaging Hypoxia-Ischemia, Brain - metabolism Hypoxia-Ischemia, Brain - therapy Infant Infant, Newborn Infants Intensive care units Lactic acid Magnetic resonance imaging Magnetic Resonance Spectroscopy Male N-Acetylaspartate Neonates Neurodevelopmental disorders Neuroprotection Newborn babies NMR Nuclear magnetic resonance Prospective Studies Protons Scanners Software Spectrum analysis Thalamus Traumatic brain injury Treatment Outcome |
| Title | Magnetic resonance spectroscopy assessment of brain injury after moderate hypothermia in neonatal encephalopathy: a prospective multicentre cohort study |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1474442218303259 https://dx.doi.org/10.1016/S1474-4422(18)30325-9 https://www.ncbi.nlm.nih.gov/pubmed/30447969 https://www.proquest.com/docview/2155054490 https://www.proquest.com/docview/2135636350 https://pubmed.ncbi.nlm.nih.gov/PMC6291458 |
| Volume | 18 |
| WOSCitedRecordID | wos000453007700021&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-4465 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0021481 issn: 1474-4422 databaseCode: 7RV dateStart: 20020501 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest - Health & Medical Complete保健、医学与药学数据库 customDbUrl: eissn: 1474-4465 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0021481 issn: 1474-4422 databaseCode: 7X7 dateStart: 20020501 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-4465 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0021481 issn: 1474-4422 databaseCode: BENPR dateStart: 20020501 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1474-4465 dateEnd: 20251009 omitProxy: false ssIdentifier: ssj0021481 issn: 1474-4422 databaseCode: M2M dateStart: 20020501 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LbxMxELZoihAX3o9AqYzEAQ5L47Ud21wQoFYcSFSVCuVmeXftJqjsLkmKlH_Cz2XG-ygFQZG4rJLszCbWTMbf2J5vCHlmpEy9YjLJnYAERfIiMTLAq6IQWAmamRAp8z-o6VTPZuawXXBbtccqu5gYA3VR5bhGvpdGLC2EGb2uvybYNQp3V9sWGltkG5nKxIBsv92fHh71KReA_ZhyCSUSIdL0vIZn72P_4XOmX0AkT2Vi_jQ7_Y4-fz1E-dOsdHDzf8dzi9xo8Sh90zjQbXLFl3fItUm7436XfJ-4kxILHSnk5RWyc3gaqzORBbOqN9T11J60CjTDjhN0UX4GU9HYf5xirx3ko6DzTR3Lvb4sHEjQ0uPCPXw3xpZ67k4r7I68eUUdhaF0FaA0nniMo_cUu_ku1zRS4t4jxwf7x-_eJ203hyQH1LROCuM0cs8zxwop88KpjOecZ1wrVWivQ5YGgPpy7DmkcMIZPcpVoTgrGMsgLt8ng7Iq_UNCYQrlIeRCepDzAVmwdPAuMJUFxZUbEtEZ0eYt0zk23Di1_ZE2tL1F21umbbS9NUPyslerG6qPyxTGnYfYro4VIq-FyegyRd0rtkCnATD_orrTuZNto83KnvvSkDztb0OcwM0fB-Y8QxkuxxzgJcg8aDy3HyUfCaHMGB6uLvh0L4Ac5BfvlIt55CIfp4YJqR_9_Wc9JtcBaJpm6WqHDNbLM_-EXM2_rRer5S7ZUkef8DpT8ap3278xvJukkx_hOE0W |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxELaqgoAL70eggJFAgsO28dqObSSEEFC1ahIhiFBvlnfXJkFlE5IUlH_Cn-A_MuN9lIKgXHrgFmVn8vB-nsd65htCHhopU6-YTHInIEGRvEiMDPCqKAR2gmYmRMr8vhoO9f6-ebNGvje9MFhW2djEaKiLaY7PyLfSGEsLYbrPZ58TnBqFp6vNCI0KFnt-9RVStsWz3Vdwfx-l6fbr0cudpJ4qkOTgvZdJYZxGDnTmWCFlXjiV8ZzzjGulCu11yNIAIafseQ6phHBGd3NVKM4KxjKGQyLA4p8BM86wgky9fd_md5BZxPxOKJEIkaZHDUNb79o3HzP9BNxGKhPzJ1f4e6j7a8XmTy5w-9J_tniXycU61qYvqs1xhaz58io5N6irCa6RbwP3ocQmTjr3mJEA_mnsPEWGz-lsRV1LW0qngWY4TYNOyo8AQxpnq1OcI4RcG3S8msVWtk8TBxK09HgoAd-NdnM2dgdTnPy8ekodhZVrultprOaMi-0pTiqeL2mk-71ORqexLDfIejkt_S1CAVc8hFxID3I-IMOXDt4FprKguHIdIhrM2LxmccdhIge2LddDqFmEmmXaRqhZ0yGbrdqsojE5SaHXANI2PbrgVSw42pMUdatYB3FVcPYvqhsNem1tSRf2CLod8qC9DDYQD7Yc3M5DlOGyxyF0Bpmb1UZp_yXvCqFMDz5cHdtCrQDyqx-_Uk7GkWe9B3tcSH377z_rPjm_Mxr0bX93uHeHXICA2lSP6DbI-nJ-6O-Ss_mX5WQxvxetBSX2lDfYD5duon0 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LbxMxELaqgiou5Q2BAkYCCQ5L4rUd20gIIUpE1SaqRA-9Wd5dm6Qqm5CkoPwT_gr_jhnvoxQE5dIDt2h3ZrPrned65htCnhgpU6-YTHInIEGRvEiMDPCrKAR2gmYmRMj8PTUa6cNDs79Gvje9MFhW2djEaKiLaY7fyLtpjKWFML1uqMsi9rcHr2efE5wghTutzTiNSkR2_eorpG-LVzvb8K6fpung3cHb90k9YSDJwZMvk8I4jXjozLFCyrxwKuM55xnXShXa65ClAcJP2fcc0grhjO7lqlCcFYxlDAdGgPW_pAQ8MFYNpsM214MsI-Z6QolEiDQ9bR7qfmgPPmP6ObiQVCbmT27x97D31-rNn9zh4Op_vJDXyGYdg9M3ldJcJ2u-vEE2hnWVwU3ybeg-ltjcSeceMxXQCxo7UhH5czpbUdfCmdJpoBlO2aCT8gjEk8aZ6xTnCyEGBx2vZrHF7dPEAQUtPW5WwH-jPZ2N3fEUJ0KvXlJHYRWbrlcaqzzjwnuKE4znSxphgG-Rg4tYlttkvZyW_i6hEDbwEHIhPdD5gMhfOngXmMqC4sp1iGjkx-Y1ujsOGTm2bRkfip1FsbNM2yh21nTIi5ZtVsGbnMfQb4TTNr274G0sOODzGHXLWAd3VdD2L6xbjSTb2sIu7KkYd8jj9jTYRtzwcvA6T5CGyz6HkBpo7lRK0z4l7wmhTB8urs6oU0uAuOtnz5STccRf76eGCanv_f22HpEN0Cu7tzPavU-uQJxtqi93W2R9OT_xD8jl_Mtyspg_jIaDEnvB-vUDh7OrFA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Magnetic+resonance+spectroscopy+assessment+of+brain+injury+after+moderate+hypothermia+in+neonatal+encephalopathy%3A+a+prospective+multicentre+cohort+study&rft.jtitle=Lancet+neurology&rft.au=Lally%2C+Peter+J&rft.au=Montaldo%2C+Paolo&rft.au=Oliveira%2C+V%C3%A2nia&rft.au=Soe%2C+Aung&rft.date=2019-01-01&rft.issn=1474-4422&rft.volume=18&rft.issue=1&rft.spage=35&rft.epage=45&rft_id=info:doi/10.1016%2FS1474-4422%2818%2930325-9&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_S1474_4422_18_30325_9 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1474-4422&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1474-4422&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1474-4422&client=summon |